Skip Page Header

Home > Cannabis-based medicinal products.

National Institute for Health and Care Excellence. (2019) Cannabis-based medicinal products. London: NICE. 27 p. NICE guideline [NG144]

[img]
Preview
PDF (Cannabis-based medicinal products)
134kB

URL: https://www.nice.org.uk/guidance/NG144


This guideline covers prescribing of cannabis-based medicinal products for people with intractable nausea and vomiting, chronic pain, spasticity and severe treatment-resistant epilepsy.

 

Recommendations

This guideline includes recommendations on:

 Products covered by the guideline include:

  • cannabis-based products for medicinal use as set out by the UK Government in the 2018 Regulations
  • the licensed products delta-9-tetrahydrocannibinol combined with cannabidiol (Sativex) and nabilone
  • plant-derived cannabinoids such as pure cannabidiol (CBD)
  • synthetic compounds which are identical in structure to naturally occurring cannabinoids such as delta-9-tetrahydrocannabinol (THC), for example, dronabinol.
Item Type
Evidence resource
Publication Type
Review
Drug Type
Cannabis
Intervention Type
AOD disorder, AOD disorder drug therapy, AOD disorder harm reduction
Date
November 2019
Pages
27 p.
Publisher
NICE
Corporate Creators
National Institute for Health and Care Excellence
Place of Publication
London
EndNote

Repository Staff Only: item control page